Provides rapid relief of depressive symptoms, often within hours or days
Spravato™ is an FDA-approved prescription nasal spray containing esketamine, a novel form of ketamine, designed for treatment-resistant depression. Administered under supervision at our clinic, Spravato™ is used alongside traditional antidepressant medications to help reduce symptoms of major depressive disorder when other treatments have not been effective. On-site administration ensures patient safety and allows our team to monitor for any side effects immediately.
Provides rapid relief of depressive symptoms, often within hours or days
Targets the glutamate system in the brain, unlike typical antidepressants that focus on serotonin, dopamine, or norepinephrine
Supports neuroplasticity, helping the brain grow and adapt
Can aid in processing past events and negative memories
Shown to help with other mental health conditions such as PTSD, OCD, anxiety, and eating disorders
Administered in a safe, controlled clinical environment with psychological support before, during, and after treatment
No long-term addiction risk or known long-term side effects
Treatment involves a supervised nasal spray administration at the clinic. The standard protocol begins with visits twice per week for weeks 1–4, followed by once weekly for weeks 5–8. Patients need a driver for transportation home after each session, as mild fatigue or dissociation may occur. Maintenance therapy is typically scheduled once a week or every other week depending on your treatment plan.
Spravato™ is suitable for adults 18 years and older who have not responded adequately to at least two different antidepressants, have lost response over time, or cannot tolerate standard antidepressant doses. Your provider will determine if Spravato™ is a safe and effective addition to your personalized treatment plan.
Some patients experience short-term effects during treatment, including:
Dizziness or lightheadedness
Floating sensations
Mild dissociation, such as feeling detached from yourself, your thoughts, or your surroundings
Altered perceptions of time or space
Patients remain under supervision for approximately two hours post-treatment. A friend or family member is required to drive you home, and mild fatigue may last the rest of the day but typically resolves by the next morning.
Spravato™ is not recommended for patients with:
Aneurysmal vascular disease or arteriovenous malformations
History of intracerebral hemorrhage
Hypersensitivity to esketamine, ketamine, or any inactive ingredients
Pregnancy or breastfeeding